ESR1 and breast cancer: To our knowledge, results presented here constitute the first experimental validation of a direct role for CHK2 inhibition in promoting metastatic phenotypes in ER+/HER2− breast cancer cells, although studies from other groups indicate a role for CHK2 activation in epithelial mesenchymal transition (56, 57), often a precursor to metastasis.